This listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims

1-19. (canceled)

20. (currently amended) A method for treating a subject suffering from excessive daytime sleepiness associated with ~~narcolepsy,~~ narcolepsy, multiple sclerosis related fatigue, infertility, eating disorders, attention deficit hyperactivity disorder (ADHD), Parkinson's disease, incontinence, sleep apnea, or myopathies, which comprises administering to a subject a therapeutically effective amount of ~~Form III, Form IV, or~~ Form V of R-(-)-modafinil.

21. (original) The method according to claim 20, wherein the subject is a human subject.

22-28. (canceled)

29. (currently amended) A method for treating a subject suffering from excessive daytime sleepiness associated with ~~narcolepsy,~~ narcolepsy[[,]] or sleep apnea, which comprises administering to a subject a therapeutically effective amount of Form V of R-(-)-modafinil.

30. (previously presented) A method for treating a subject suffering from attention deficit hyperactivity disorder (ADHD), which comprises administering to a subject a therapeutically effective amount of Form V of R-(-)-modafinil.

31. (new) A method for treating a subject suffering from excessive daytime sleepiness, which comprises administering to a subject a therapeutically effective amount of Form V of R-(-)-modafinil.

32. (new) The method of claim 20, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at:

(a) 6.61, 10.39, and 16.49 degrees;

(b) 6.61 and 10.39 degrees;

(c) 13.99 and 17.73 degrees;

(d) 20.87 and 22.31 degrees; or

(e) 6.61 degrees.

33. (new) The method of claim 32, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61 degrees.

34. (new) The method of claim 33, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61 and 10.39 degrees.

35. (new) The method of claim 34, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61, 10.39, and 16.49 degrees.

36. (new) The method of claim 20, wherein the Form V of R-(-)-modafinil is substantially free of other polymorphic forms of R-(-)-modafinil.

37. (new) The method of claim 20, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form III.

38. (new) The method of claim 20, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form IV.

39. (new) The method of claim 33, wherein the Form V of R-(-)-modafinil is substantially free of other polymorphic forms of R-(-)-modafinil.

40. (new) The method of claim 33, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form III.

41. (new) The method of claim 33, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form IV.

42. (new) The method of claim 29, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at:

(a) 6.61, 10.39, and 16.49 degrees;
(b) 6.61 and 10.39 degrees;
(c) 13.99 and 17.73 degrees;
(d) 20.87 and 22.31 degrees; or
(e) 6.61 degrees.

43. (new) The method of claim 42, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61 degrees.

44. (new) The method of claim 43, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61 and 10.39 degrees.

45. (new) The method of claim 44, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61, 10.39, and 16.49 degrees.

46. (new) The method of claim 29, wherein the Form V of R-(-)-modafinil is substantially free of other polymorphic forms of R-(-)-modafinil.

47. (new) The method of claim 29, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form III.

48. (new) The method of claim 29, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form IV.

49. (new) The method of claim 43, wherein the Form V of R-(-)-modafinil is substantially free of other polymorphic forms of R-(-)-modafinil.

50. (new) The method of claim 43, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form III.

51. (new) The method of claim 43, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form IV.

52. (new) The method of claim 30, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at:

(a) 6.61, 10.39, and 16.49 degrees;

(b) 6.61 and 10.39 degrees;

(c) 13.99 and 17.73 degrees;

(d) 20.87 and 22.31 degrees; or

(e) 6.61 degrees.

53. (new) The method of claim 52, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61 degrees.

54. (new) The method of claim 53, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61 and 10.39 degrees.

55. (new) The method of claim 54, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61, 10.39, and 16.49 degrees.

56. (new) The method of claim 30, wherein the Form V of R-(-)-modafinil is substantially free of other polymorphic forms of R-(-)-modafinil.

57. (new) The method of claim 30, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form III.

58. (new) The method of claim 30, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form IV.

59. (new) The method of claim 53, wherein the Form V of R-(-)-modafinil is substantially free of other polymorphic forms of R-(-)-modafinil.

60. (new) The method of claim 53, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form III.

61. (new) The method of claim 53, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form IV.

62. (new) The method of claim 31, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at:

(a) 6.61, 10.39, and 16.49 degrees;

(b) 6.61 and 10.39 degrees;

(c) 13.99 and 17.73 degrees;

(d) 20.87 and 22.31 degrees; or

(e) 6.61 degrees.

63. (new) The method of claim 62, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61 degrees.

64. (new) The method of claim 63, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61 and 10.39 degrees.

65. (new) The method of claim 64, wherein the Form V of R-(-)-modafinil is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles at 6.61, 10.39, and 16.49 degrees.

66. (new) The method of claim 31, wherein the Form V of R-(-)-modafinil is substantially free of other polymorphic forms of R-(-)-modafinil.

67. (new) The method of claim 31, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form III.

68. (new) The method of claim 31, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form IV.

69. (new) The method of claim 63, wherein the Form V of R-(-)-modafinil is substantially free of other polymorphic forms of R-(-)-modafinil.

70. (new) The method of claim 63, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form III.

71. (new) The method of claim 63, wherein the Form V of R-(-)-modafinil is substantially free of R-(-)-modafinil Form IV.